JPWO2023097291A5 - - Google Patents

Info

Publication number
JPWO2023097291A5
JPWO2023097291A5 JP2024531113A JP2024531113A JPWO2023097291A5 JP WO2023097291 A5 JPWO2023097291 A5 JP WO2023097291A5 JP 2024531113 A JP2024531113 A JP 2024531113A JP 2024531113 A JP2024531113 A JP 2024531113A JP WO2023097291 A5 JPWO2023097291 A5 JP WO2023097291A5
Authority
JP
Japan
Prior art keywords
item
modified oligonucleotide
compound
items
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541771A5 (https=
JP2024541771A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080448 external-priority patent/WO2023097291A1/en
Publication of JP2024541771A publication Critical patent/JP2024541771A/ja
Publication of JP2024541771A5 publication Critical patent/JP2024541771A5/ja
Publication of JPWO2023097291A5 publication Critical patent/JPWO2023097291A5/ja
Pending legal-status Critical Current

Links

JP2024531113A 2021-11-24 2022-11-23 補体因子bを調節する組成物及びその使用方法 Pending JP2024541771A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163283177P 2021-11-24 2021-11-24
US63/283,177 2021-11-24
US202163287952P 2021-12-09 2021-12-09
US63/287,952 2021-12-09
US202263302976P 2022-01-25 2022-01-25
US63/302,976 2022-01-25
US202263339873P 2022-05-09 2022-05-09
US63/339,873 2022-05-09
PCT/US2022/080448 WO2023097291A1 (en) 2021-11-24 2022-11-23 Complement factor b-modulating compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024541771A JP2024541771A (ja) 2024-11-12
JP2024541771A5 JP2024541771A5 (https=) 2025-12-03
JPWO2023097291A5 true JPWO2023097291A5 (https=) 2025-12-03

Family

ID=86540402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531113A Pending JP2024541771A (ja) 2021-11-24 2022-11-23 補体因子bを調節する組成物及びその使用方法

Country Status (14)

Country Link
US (1) US12595477B2 (https=)
EP (1) EP4437104A4 (https=)
JP (1) JP2024541771A (https=)
KR (1) KR20240107360A (https=)
CN (1) CN119256083A (https=)
AU (1) AU2022396536A1 (https=)
CA (1) CA3240273A1 (https=)
CL (1) CL2024001561A1 (https=)
CO (1) CO2024006751A2 (https=)
IL (1) IL312928A (https=)
MX (1) MX2024006368A (https=)
PE (1) PE20241340A1 (https=)
TW (1) TW202340463A (https=)
WO (1) WO2023097291A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024197017A2 (en) 2023-03-21 2024-09-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of complement factor b (cfb) pharmaceutical compositions thereof, and methods of use
WO2025026228A1 (zh) * 2023-07-28 2025-02-06 苏州炫景生物科技有限公司 Cfb抑制剂组合物及其应用
WO2025151250A2 (en) * 2024-01-09 2025-07-17 Adarx Pharmaceuticals, Inc. Complement factor b-modulating compositions and methods of use thereof
WO2025256564A1 (en) * 2024-06-12 2025-12-18 Qilu Pharmaceutical Co., Ltd. iRNA COMPOSITION AND METHOD OF USING SAME

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
CN105143450A (zh) 2013-01-08 2015-12-09 贝尼泰克生物制药有限公司 年龄相关性黄斑变性治疗
DK3043827T3 (da) 2013-09-13 2019-08-26 Ionis Pharmaceuticals Inc Modulatorer af komplement faktor b
SG10201804960RA (en) 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
SG11201608502TA (en) 2014-05-01 2016-11-29 Ionis Pharmaceuticals Inc Compositions and methods for modulating complement factor b expression
MX2020004897A (es) 2017-11-13 2020-10-05 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula.
MX2022013606A (es) 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
KR20240051221A (ko) 2021-09-02 2024-04-19 사일런스 테라퓨틱스 게엠베하 세포에서 보체 인자 b (cfb)의 발현을 억제하기 위한 핵산
US20240401045A1 (en) * 2021-10-01 2024-12-05 Adarx Pharmaceuticals, Inc. Angiotensinogen-modulating compositions and methods of use thereof
TW202333749A (zh) 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 補體因子b(cfb)irna組成物及其使用方法

Similar Documents

Publication Publication Date Title
JP7478210B2 (ja) 修飾オリゴヌクレオチド及び使用方法
US20070179112A1 (en) Polymeric nucleoside prodrugs
WO1994022891A1 (en) Oligonucleotides with amide linkages replacing phosphodiester linkages
JP2021515784A5 (https=)
JP2021090458A5 (https=)
JP2009524696A5 (https=)
AR127325A1 (es) Métodos y composiciones para el tratamiento de la enfermedad renal poliquística
EP0701564A1 (en) Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
JPWO2017218454A5 (https=)
JP2000512630A (ja) 2’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体
JPWO2023097291A5 (https=)
JP2018518167A5 (https=)
JPWO2019175260A5 (https=)
Beck et al. A double-headed nucleotide with two cytosines: DNA with condensed information and improved duplex stability
JPWO2020158687A5 (https=)
TW202345861A (zh) 經修飾之間隔體寡聚物及其使用方法
JPWO2023056446A5 (https=)
JP7818760B2 (ja) ヌクレオシド誘導体の製造方法
JPWO2023192630A5 (https=)
JPWO2019169219A5 (https=)
JPWO2023056440A5 (https=)
TWI871840B (zh) 合成4'-磷酸鹽類似物核苷酸亞磷醯胺之方法
JPWO2022204430A5 (https=)
WO1995031470A2 (en) Antisense inhibitors of gene expression
JPWO2019200172A5 (https=)